Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ferriprotoporphyrin IX (FP-IX), commonly known as free heme, is a potent toxin produced by Plasmodium falciparum during its consumption of host hemoglobin within red blood cells (Hempelmann, 2007, Parasitology Research). Because the parasite lacks a heme-degrading enzyme like heme oxygenase, it must detoxify the released FP-IX by sequestering it into an insoluble crystalline polymer called hemozoin, or malaria pigment (Sullivan, 2002, International Journal for Parasitology). This detoxification pathway is essential for parasite survival, as free heme can generate reactive oxygen species and disrupt cellular membranes (Egan, 2008, Journal of Inorganic Biochemistry). Many classic antimalarial drugs, particularly the quinolines like chloroquine and quinine, target this process by binding directly to free heme (PubChem, CID 5460340). This binding prevents the formation of hemozoin, causing toxic heme-drug complexes to accumulate within the parasite's digestive vacuole. The resulting oxidative stress and membrane damage ultimately lead to the death of the parasite. Resistance to these drugs often arises from mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT), which pumps the drugs out of the digestive vacuole (Fidock et al., 2000, Molecular Cell). Understanding the interaction between FP-IX and antimalarials remains a cornerstone of malaria drug discovery and resistance monitoring.
Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme and heme-drug complexes that cause membrane damage and parasite death.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ferriprotoporphyrin IX (FP-IX) (FP-IX).